drugset / Trial / NCT06057103

A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects

NCT06057103

Phase 1 Completed 18 enrolled Nanjing Zenshine Pharmaceuticals
Non-randomizedCrossoverOpen-labelTreatment

Summary

The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in healthy Chinese adult subjects. The seongdary object is evaluating combined or uncombined multiple oral oseltamivir phosphate in healthy Chinese adult subjects.

Timeline

Start
2023-08-28
Primary completion
2023-12-05
Completion
2024-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 75 mg Oral
Subject ZX-7101A Unknown 80 mg Oral

Indications

No indication recorded.